This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Endocyte Reports First Quarter 2013 Financial Results And Business Update

Stocks in this article: ECYT

Preparing for Potential Commercialization in Europe and Expanding SMDC Pipeline

Conference call today at 4:30 p.m. EDT

WEST LAFAYETTE, Ind., May 2, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced financial results for the first quarter ending March 31, 2013, and provided a business update.

"Enrollment for the PROCEED and TARGET trials for vintafolide and etarfolatide continued on schedule during the first quarter, and we began to establish a strong commercial presence in Europe in anticipation of potential EU approval at the end of the year," said Ron Ellis, Endocyte's president and chief executive officer.

"We are encouraged by the progression of our robust pipeline, based on our unique targeted approach to drug development," Ron Ellis added. "That includes a recent presentation of the first clinical data to demonstrate the involvement of activated macrophage cells in osteoarthritis. We have demonstrated the ability to target this cell in numerous inflammatory indications and are preparing both the imaging diagnostic and therapeutic drug candidates for the clinical study next year. We also have been preparing our folate-targeted tubulysin drug candidate EC1456 to enter the clinic. We are completing the pre-clinical studies and expect to begin that Phase 1 trial in the third quarter."

First Quarter 2013 Financial Results

Endocyte reported a net loss of $3.9 million, or $0.11 per basic and diluted share for the first quarter of 2013, compared to a net loss of $9.8 million, or $0.27 per basic and diluted share, for the same period in 2012.

Revenue was $14.5 million for the first quarter of 2013 associated with the collaboration with Merck. Of this revenue, $13.0 million related to the amortization of the $120.0 million upfront license payment, the $5.0 million milestone payment received related to the marketing authorization application (MAA) filings in the EU during the fourth quarter of 2012, and the $13.6 million in reimbursable research and development expenditures incurred prior to the first quarter of 2013. The remaining $1.5 million of revenue related to amortization of reimbursable research and development expenditures incurred during the first quarter of 2013. The amortization for both the upfront license fee and ongoing research and development services is recognized as revenue ratably over a performance period that began at the closing date of the agreement, April 27, 2012, and is expected to conclude at the end of 2014.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs